Publications by authors named "Metod Oblak"
Background: Patients' experience of symptoms often goes undetected during consultation in an outpatient clinic, and the use of a patient-reported outcome measure (PRO) in such a setting could be useful to aid treatment decision-making. A new PRO measure, the HM-PRO (Hematological Malignancy Specific Patient-Reported Outcome Measure) has been recently developed to evaluate hematological malignancy (HM) patients' health-related quality of life (HRQoL) and their symptom experience in daily clinical practice as well as in research. The objectives of the study were to assess: the internal consistency of the scores for Part A (impact) and its four domains (physical behavior; social well-being; emotional behavior; and eating and drinking habits) and Part B (signs and symptoms); and the test-retest reliability of the individual items of the newly developed hematological malignancy specific composite measure, the HM-PRO.
View Article and Find Full Text PDFBackground: Validity is the ability of an instrument to measure what it claims to measure. It means the degree to which the empirical evidence supports the trustworthiness of interpretations based on the calculated scores. The hematological malignancy (HM) specific patient reported outcome measure (HM-PRO), is a newly developed instrument for use in daily clinical practice as well as in research.
View Article and Find Full Text PDFArticle Synopsis
- Aberrant NF-κB activity is linked to the development and survival of multiple myeloma (MM) and various other cancers, yet no specific inhibitors have been approved clinically due to harmful side effects from existing drugs.
- Researchers have developed a new inhibitor called DTP3, which selectively targets a cancer-specific survival mechanism related to NF-κB, effectively killing MM cells without harming healthy ones.
- Preclinical studies show that DTP3 has favorable properties, including effectiveness against cancer, a long-lasting presence in the body, and no toxic effects, leading to its approval for clinical trials in cancer treatment.
To determine measurement equivalence of paper and electronic application of the hematological malignancy-patient-reported outcome (HM-PRO), a specific measure for the evaluation of patient-reported outcomes in HMs. Following International Society of Pharmacoeconomics and Outcomes Research ePRO Good Research Practice Task Force guidelines, a total of 193 adult patients with different HMs were recruited into a multicenter prospective study. The paper and the electronic version of the instrument were completed in the outpatient clinics in a randomized crossover design with a 30 min time interval to minimize the learning effect.
View Article and Find Full Text PDF